Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.14 (¥4,142)-1.64%▼ (in JPY terms)
SoftBank|$22.40 (¥3,549)-10.83%▼ (in JPY terms)
MUFG|$20.35 (¥3,224)-6.52%▼ (in JPY terms)
Keyence|$440.27 (¥69,750)-3.65%▼ (in JPY terms)
Nintendo|$51.62 (¥8,178)-7.91%▼ (in JPY terms)
NTT|$1.01 (¥160)-2.85%▼ (in JPY terms)
Takeda|$41.41 (¥6,560)-4.76%▼ (in JPY terms)
Tokyo Electron|$52.16 (¥8,263)-5.60%▼ (in JPY terms)
Recruit|$107.31 (¥17,000)-5.61%▼ (in JPY terms)
ITOCHU|$14.15 (¥2,241)-6.45%▼ (in JPY terms)
Honda|$11.56 (¥1,831)-5.69%▼ (in JPY terms)
Shin-Etsu|$33.53 (¥5,312)-6.69%▼ (in JPY terms)
Tokio Marine|$3.60 (¥570)-5.97%▼ (in JPY terms)
Fast Retailing|$492.03 (¥77,950)-3.79%▼ (in JPY terms)
Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.14 (¥4,142)-1.64%▼ (in JPY terms)
SoftBank|$22.40 (¥3,549)-10.83%▼ (in JPY terms)
MUFG|$20.35 (¥3,224)-6.52%▼ (in JPY terms)
Keyence|$440.27 (¥69,750)-3.65%▼ (in JPY terms)
Nintendo|$51.62 (¥8,178)-7.91%▼ (in JPY terms)
NTT|$1.01 (¥160)-2.85%▼ (in JPY terms)
Takeda|$41.41 (¥6,560)-4.76%▼ (in JPY terms)
Tokyo Electron|$52.16 (¥8,263)-5.60%▼ (in JPY terms)
Recruit|$107.31 (¥17,000)-5.61%▼ (in JPY terms)
ITOCHU|$14.15 (¥2,241)-6.45%▼ (in JPY terms)
Honda|$11.56 (¥1,831)-5.69%▼ (in JPY terms)
Shin-Etsu|$33.53 (¥5,312)-6.69%▼ (in JPY terms)
Tokio Marine|$3.60 (¥570)-5.97%▼ (in JPY terms)
Fast Retailing|$492.03 (¥77,950)-3.79%▼ (in JPY terms)

2026-10-23 Otsuka Holdings Co.,Ltd. “The final results of the Phase 3 trial of the IgA nephropathy treatment drug "VOYXACT® (sibeprenelimab)" were presented at the American Society of Nephrology (ASN) meeting – demonstrating stabilization of renal function and reduction of the risk of disease progression and renal failure, offering new hope to patients with IgA nephropathy.”

2026-10-23 Otsuka Holdings Co.,Ltd. “The final results of the Phase 3 trial of the IgA nephropathy treat … 続きを読む

2026-10-23 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for an additional indication in combination with pembrolizumab for resectable muscle-invasive bladder cancer, regardless of whether cisplatin is indicated.”

2026-10-23 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received a … 続きを読む